NCT04555486View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

September 7, 2021

Study Completion Date

September 7, 2021

Conditions
Primary Hyperoxaluria Type 3
Interventions
DRUG

DCR-PHXC

Intervention, drug, DCR-PHXC

DRUG

Sterile Normal Saline (0.9% NaCl)

Placebo comparator

Trial Locations (6)

10016

Clinical Trial Site, New York

53127

Clinical Trial Site, Bonn

55905

Clinical Trial Site, Rochester

02115

Clinical Trial Site, Boston

1105 AZ

Clinical Trial Site, Amsterdam

NW3 2QG

Clinical Trial Site, London

All Listed Sponsors
lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY

NCT04555486 - Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients | Biotech Hunter | Biotech Hunter